Pasithea Therapeutics Corp (KTTA)

$0.55 -0.02 (-3.02%)
Market Cap 13.71M
Revenue (ttm) 0.00
Net Income (ttm) -20.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 421,700
Avg Vol 915,722
Day's Range N/A - N/A
Shares Out 24.94M
Stochastic %K 57%
Beta 0.29
Analysts Sell
Price Target $3.00

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, includ...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 977 3380
Address:
1111 Lincoln Road, Suite 500, Miami Beach, United States
UtahSUV
UtahSUV Jul. 2 at 2:50 PM
$KTTA the only research this company has done was to scam people from their money
0 · Reply
Aldinho_lbk
Aldinho_lbk Jul. 1 at 1:35 PM
$KTTA let it run... No auto stop loss...
0 · Reply
letuan7
letuan7 Jul. 1 at 4:38 AM
$KTTA wow this piece of shi🌞 52 week high only $2.X 🤣🤣🤣🤣🤣 maybe .7 tomorrow if lucky
0 · Reply
letuan7
letuan7 Jun. 30 at 11:54 PM
$KTTA chased .58 sold for loss chased .55 bags again piece of shit 🗑️🗑️🗑️🗑️🗑️🗑️🗑️🗑️🗑️🗑️
0 · Reply
M113
M113 Jun. 30 at 11:52 PM
$KTTA wel not the close we wanted
0 · Reply
topstockalerts
topstockalerts Jun. 30 at 11:49 PM
After Hours Top Gainers PT2 $XTLB $CEPO $ALZN $ATXG $KTTA
0 · Reply
letuan7
letuan7 Jun. 30 at 10:41 PM
$KTTA only phase 1 🤣🤣🤣🤣
0 · Reply
topstockalerts
topstockalerts Jun. 30 at 9:33 PM
$KTTA there’s a quiet confidence to this move.
0 · Reply
Aldinho_lbk
Aldinho_lbk Jun. 30 at 8:22 PM
$KTTA people amazes me... This stock is a low float, have good news, and yet peice goes down because auto stop loss... Ay ay ay, tamales ..
0 · Reply
BioTuesdays
BioTuesdays Jun. 30 at 7:13 PM
$KTTA has announced updated interim safety and clinical activity data from its ongoing first-in-human trial of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, including those who have failed prior BRAF/MEK inhibitor treatment. https://biotuesdays.com/2026/06/30/pasithea-reports-positive-interim-phase-1-cancer-study-data/
0 · Reply
Latest News on KTTA
Pasithea Therapeutics announces updated data from PAS-004 trial

2026-06-30T11:15:44.000Z - 4 days ago

Pasithea Therapeutics announces updated data from PAS-004 trial

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

Jun 30, 2026, 7:00 AM EDT - 4 days ago

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

Pasithea Therapeutics announces amendments to PAS-004 clinical study

2026-06-16T11:20:20.000Z - 18 days ago

Pasithea Therapeutics announces amendments to PAS-004 clinical study

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

Jun 16, 2026, 7:00 AM EDT - 18 days ago

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

PN

Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference

Jun 15, 2026, 7:02 AM EDT - 19 days ago

Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference

Pasithea Therapeutics Transcript: Transcript

Jun 15, 2026, 5:21 AM EDT - 19 days ago

Pasithea Therapeutics Transcript: Transcript

Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA

2026-06-02T11:30:51.000Z - 4 weeks ago

Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Jun 2, 2026, 7:02 AM EDT - 4 weeks ago

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

2026-05-29T17:55:12.000Z - 5 weeks ago

Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer

2026-05-04T11:32:53.000Z - 2 months ago

Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

May 4, 2026, 7:01 AM EDT - 2 months ago

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004

2026-04-20T11:26:07.000Z - 2 months ago

Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Apr 1, 2026, 7:01 AM EDT - 3 months ago

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 7:01 AM EST - 4 months ago

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Pasithea Therapeutics provides updated timeline on PAS-004 programs

2026-01-13T12:11:53.000Z - 6 months ago

Pasithea Therapeutics provides updated timeline on PAS-004 programs

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Jan 13, 2026, 7:01 AM EST - 6 months ago

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Pasithea Therapeutics initiated with a Buy at H.C. Wainwright

2025-12-08T11:15:53.000Z - 7 months ago

Pasithea Therapeutics initiated with a Buy at H.C. Wainwright

3 Penny Stocks to Watch Now, 12/2/25

2025-12-02T16:19:00.000Z - 7 months ago

3 Penny Stocks to Watch Now, 12/2/25

BEAM

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Dec 2, 2025, 7:00 AM EST - 7 months ago

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics prices 80M shares at 75c in public offering

2025-11-28T14:25:15.000Z - 7 months ago

Pasithea Therapeutics prices 80M shares at 75c in public offering

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Nov 28, 2025, 9:20 AM EST - 7 months ago

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics announces $1M award by ALS Association

2025-11-25T12:05:49.000Z - 7 months ago

Pasithea Therapeutics announces $1M award by ALS Association

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

2025-11-24T12:15:27.000Z - 7 months ago

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Nov 24, 2025, 7:00 AM EST - 7 months ago

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Pasithea says tablet PK exposure increases proprtionally with dose increase

2025-11-21T17:40:13.000Z - 8 months ago

Pasithea says tablet PK exposure increases proprtionally with dose increase

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Nov 21, 2025, 12:35 PM EST - 8 months ago

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Why Is Pasithea Therapeutics Stock (KTTA) Down Today?

2025-11-21T14:02:21.000Z - 8 months ago

Why Is Pasithea Therapeutics Stock (KTTA) Down Today?

Pasithea Therapeutics announces interim data from PAS-004 trial

2025-11-20T21:05:17.000Z - 8 months ago

Pasithea Therapeutics announces interim data from PAS-004 trial

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

Nov 20, 2025, 4:01 PM EST - 8 months ago

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

Pasithea announces activation of trial site at UAB for study of PAS-004

2025-11-04T12:50:47.000Z - 8 months ago

Pasithea announces activation of trial site at UAB for study of PAS-004

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Nov 4, 2025, 7:03 AM EST - 8 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics announces activation of two South Korean trial sites

2025-09-16T11:15:43.000Z - 10 months ago

Pasithea Therapeutics announces activation of two South Korean trial sites

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Sep 16, 2025, 7:03 AM EDT - 10 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea announces enrollment of cohort 2 in Phase 1/1b trial of PAS-004

2025-09-08T11:11:03.000Z - 10 months ago

Pasithea announces enrollment of cohort 2 in Phase 1/1b trial of PAS-004

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 8:39 AM EDT - 11 months ago

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Jul 31, 2025, 7:01 AM EDT - 1 year ago

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Jun 11, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Jun 2, 2025, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

May 20, 2025, 7:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

May 14, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

May 7, 2025, 5:00 PM EDT - 1 year ago

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

May 6, 2025, 11:10 AM EDT - 1 year ago

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

May 6, 2025, 7:03 AM EDT - 1 year ago

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Apr 29, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Apr 24, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Apr 10, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Feb 5, 2025, 6:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Jan 14, 2025, 8:02 AM EST - 1 year ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 26, 2024, 6:44 PM EDT - 1 year ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Sep 26, 2024, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Sep 9, 2024, 8:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Sep 3, 2024, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 9:11 AM EDT - 2 years ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

May 28, 2024, 6:59 AM EDT - 2 years ago

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 29, 2024, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Apr 24, 2024, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Feb 13, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Jan 8, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Jan 2, 2024, 8:35 AM EST - 2 years ago

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Dec 28, 2023, 5:00 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Dec 19, 2023, 5:19 PM EST - 2 years ago

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Dec 11, 2023, 8:01 AM EST - 2 years ago

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Nov 29, 2023, 4:27 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Nov 29, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Nov 9, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Sep 14, 2023, 8:30 AM EDT - 3 years ago

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 4:14 PM EDT - 3 years ago

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Aug 1, 2023, 7:59 AM EDT - 3 years ago

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Jul 20, 2023, 8:43 AM EDT - 3 years ago

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

UtahSUV
UtahSUV Jul. 2 at 2:50 PM
$KTTA the only research this company has done was to scam people from their money
0 · Reply
Aldinho_lbk
Aldinho_lbk Jul. 1 at 1:35 PM
$KTTA let it run... No auto stop loss...
0 · Reply
letuan7
letuan7 Jul. 1 at 4:38 AM
$KTTA wow this piece of shi🌞 52 week high only $2.X 🤣🤣🤣🤣🤣 maybe .7 tomorrow if lucky
0 · Reply
letuan7
letuan7 Jun. 30 at 11:54 PM
$KTTA chased .58 sold for loss chased .55 bags again piece of shit 🗑️🗑️🗑️🗑️🗑️🗑️🗑️🗑️🗑️🗑️
0 · Reply
M113
M113 Jun. 30 at 11:52 PM
$KTTA wel not the close we wanted
0 · Reply
topstockalerts
topstockalerts Jun. 30 at 11:49 PM
After Hours Top Gainers PT2 $XTLB $CEPO $ALZN $ATXG $KTTA
0 · Reply
letuan7
letuan7 Jun. 30 at 10:41 PM
$KTTA only phase 1 🤣🤣🤣🤣
0 · Reply
topstockalerts
topstockalerts Jun. 30 at 9:33 PM
$KTTA there’s a quiet confidence to this move.
0 · Reply
Aldinho_lbk
Aldinho_lbk Jun. 30 at 8:22 PM
$KTTA people amazes me... This stock is a low float, have good news, and yet peice goes down because auto stop loss... Ay ay ay, tamales ..
0 · Reply
BioTuesdays
BioTuesdays Jun. 30 at 7:13 PM
$KTTA has announced updated interim safety and clinical activity data from its ongoing first-in-human trial of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, including those who have failed prior BRAF/MEK inhibitor treatment. https://biotuesdays.com/2026/06/30/pasithea-reports-positive-interim-phase-1-cancer-study-data/
0 · Reply
Aldinho_lbk
Aldinho_lbk Jun. 30 at 5:06 PM
$KTTA shoet sellers trying hard boxing up this stock... Dudes, cant you see the price is heading up?
0 · Reply
SupremeTrader93
SupremeTrader93 Jun. 30 at 4:07 PM
$LGCL 🔥🔥🔥 squeezing $EDBL $KTTA $GVH $BIYA
0 · Reply
Aldinho_lbk
Aldinho_lbk Jun. 30 at 3:54 PM
$KTTA lunch hour is here, lets get ready for a 🚀🚀🚀 🐔
0 · Reply
IntentionalTrades
IntentionalTrades Jun. 30 at 2:44 PM
$KTTA I am riding back the POS
0 · Reply
Pig2market
Pig2market Jun. 30 at 2:34 PM
$KTTA good gosh, make a decision.
0 · Reply
Barryman1
Barryman1 Jun. 30 at 1:41 PM
$KTTA what does it need more to run 🆙?
0 · Reply
Risky_Behavoir
Risky_Behavoir Jun. 30 at 1:18 PM
$KTTA
0 · Reply
Riskkky
Riskkky Jun. 30 at 1:02 PM
$KTTA This stock used to run hard but not anymore i guess ?
0 · Reply
WannabeTrad3r
WannabeTrad3r Jun. 30 at 12:52 PM
$KTTA could this be a dud ?
0 · Reply
IntentionalTrades
IntentionalTrades Jun. 30 at 12:46 PM
$KTTA Short position closed with a nice profit
0 · Reply
Barryman1
Barryman1 Jun. 30 at 12:35 PM
$KTTA time to go up now
0 · Reply
Floridaflipper
Floridaflipper Jun. 30 at 12:19 PM
$KTTA ready to head north
0 · Reply